US › Healthcare

Brainstorm Cell Therapeutics Inc (BCLI)

US · Healthcare · Biotechnology

$0.78+1.30%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$178,000

Net profit

$-2.1M

Profit YoY

+25.7%

EPS

$-0.19

EPS estimate

$-0.36

Net margin

-1,194.9%

EPS came in at -0.19 against a street estimate of -0.36 — a beat of 47.2%.

Key statistics

Market cap

$9.9M

Forward P/E

0.0

P/B

54.50

Book value

$-1.00

EPS (TTM)

$-0.85

52-week high

$1.69

52-week low

$0.46

50-day MA

$0.91

200-day MA

$0.73

Beta

0.22

Analyst view

Analysts rate Brainstorm Cell Therapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $17.00.

Shareholding

Insiders

11.18%

Largest institutional holders

Fund	Stake
BNP Paribas Arbitrage, SA	0.00%
VSM Wealth Advisory, LLC	0.00%
Advisor Group Holdings, Inc.	0.00%
St Germain D J Co Inc	0.00%
Steward Partners Investment Advisory, LLC	0.00%
Bangor Savings Bank	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Brainstorm Cell Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.